<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743375</url>
  </required_header>
  <id_info>
    <org_study_id>Med Chula IRB 143/63</org_study_id>
    <nct_id>NCT04743375</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Silk Sericin Dressing With Collagen for Split-thickness Skin Graft Donor Site Treatment</brief_title>
  <official_title>Clinical Efficacy of Silk Sericin Dressing With Collagen for Split-thickness Skin Graft Donor Site Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the efficacy and safety of sericin dressing with collagen in STSG donor site&#xD;
      treatment comparing with Bactigras®. Around 30 patients will be enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Wounds are a public health problem found worldwide that associated with both clinical and&#xD;
      economic burdens. Although several wound dressings are available, some limitations of those&#xD;
      dressings still existed resulting in the need for new wound dressing development.&#xD;
&#xD;
      The sericin dressing with collagen was developed to provide a moist environment and bioactive&#xD;
      ingredients to the wound bed. To evaluate its efficacy and safety, the STSG donor sites of&#xD;
      each patient will be divided into two equal areas. Each area will be randomly allocated into&#xD;
      sericin dressing with collagen group or control group (Bactigras®). The outcomes will be&#xD;
      collected to examine the efficacy and safety of sericin dressing with collagen in comparison&#xD;
      with commercial dressing Bactigras®.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to complete healing</measure>
    <time_frame>42 days</time_frame>
    <description>The number of days since starting treatment until the primary dressing can spontaneously detach from wound with full re-epithelialization (at least 95% re-epithelialization) without any drainage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>42 days</time_frame>
    <description>Pain score evaluated by patient using visual analog scales (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>42 days</time_frame>
    <description>The incidence of infection will be reported as &quot;present&quot; or &quot;not present&quot;. Infection wound is wound which has purulent secretion or some of the inflammatory reactions (erythema, warmth, pain or tenderness, or induration) and has positive result from microbiological test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effect</measure>
    <time_frame>42 days</time_frame>
    <description>Adverse effects on hepatic function, renal function, and other adverse effects resulted from dressing application will be reported as &quot;present&quot; or &quot;not present&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vancouver scar scale (VSS)</measure>
    <time_frame>6 months</time_frame>
    <description>Vancouver scar scale evaluated by clinician at 1, 3, and 6 months after complete wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient scale of Patient and observer scar scale (POSAS)</measure>
    <time_frame>6 months</time_frame>
    <description>Patient scale of Patient and observer scar scale (POSAS) evaluated by patients 6 months after complete wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema level</measure>
    <time_frame>6 months</time_frame>
    <description>Erythema level measured by using Mexameter® at 1, 3, and 6 months after complete wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melanin level</measure>
    <time_frame>6 months</time_frame>
    <description>Melanin level measured by using Mexameter® at 1, 3, and 6 months after complete wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trans-epidermal water loss (TEWL)</measure>
    <time_frame>6 months</time_frame>
    <description>TEWL measured by using Tewameter® at 1, 3, and 6 months after complete wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin hydration</measure>
    <time_frame>6 months</time_frame>
    <description>Hydration level measured by using Corneometer® at 1, 3, and 6 months after complete wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin elasticity</measure>
    <time_frame>6 months</time_frame>
    <description>Elasticity parameters measured by using Cutometer® at 1, 3, and 6 months after complete wound healing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Wound Heal</condition>
  <condition>Wound Surgical</condition>
  <condition>Donor Site Complication</condition>
  <arm_group>
    <arm_group_label>Sericin dressing with collagen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sericin dressing with collagen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bactigras</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercial dressing</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>wound dressing application</intervention_name>
    <description>Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.</description>
    <arm_group_label>Bactigras</arm_group_label>
    <arm_group_label>Sericin dressing with collagen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have STSG donor site wounds on the thigh area&#xD;
&#xD;
          -  Age more than 18 years old&#xD;
&#xD;
          -  The split-thickness skin graft is harvested for the first time at the investigated&#xD;
             area.&#xD;
&#xD;
          -  Patients who are able to communicate with the Thai language&#xD;
&#xD;
          -  Willingness to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a mental disorder or immunocompromised diseases&#xD;
&#xD;
          -  Patients who cannot or not willing to follow the protocol&#xD;
&#xD;
          -  Known sensitivity or allergy to sericin, chlorhexidine, and collagen&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pornanong Aramwit, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pornanong Aramwit, Ph.D</last_name>
    <phone>+66899217255</phone>
    <email>aramwit@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chulalongkorn Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pornanong Aramwit, Ph.D.</last_name>
      <phone>+66-89-9217255</phone>
      <email>aramwit@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pornanong Aramwit, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Pornanong Aramwit, Pharm.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Wound dressing</keyword>
  <keyword>Sericin</keyword>
  <keyword>Collagen</keyword>
  <keyword>Split-thickness skin graft donor site (STSG donor site)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

